News
MIST
1.737
-0.16%
-0.003
Weekly Report: what happened at MIST last week (0513-0517)?
Weekly Report · 5h ago
Milestone Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Dow Jones · 4d ago
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Benzinga · 4d ago
Milestone Pharmaceuticals’ Strong Buy Rating: CARDAMYST’s FDA Resubmission and Bright Revenue Prospects
TipRanks · 4d ago
Analysts’ Top Healthcare Picks: Outset Medical (OM), Cytokinetics (CYTK)
TipRanks · 6d ago
MIST Stock Earnings: Milestone Pharmaceuticals Beats EPS for Q1 2024
Milestone Pharmaceuticals reported earnings per share of -21 cents for the first quarter of 2024. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -26 cents. Milestone pharmaceuticals just reported results for first quarter.
Investorplace · 6d ago
Milestone Pharmaceuticals Excels with New Drug Update
TipRanks · 05/13 13:37
Milestone Pharmaceuticals Inc. Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2024
Press release · 05/13 12:56
Milestone Pharmaceuticals GAAP EPS of -$0.21 beats by $0.05
Milestone Pharmaceuticals Inc. GAAP EPS of -$ beats by $. There was no revenue for the first quarter ended March 31, 2024 compared to $ million in the second quarter of 2023. The company's stock is up 2.7% in the last day of trading.
Seeking Alpha · 05/13 12:42
MILESTONE PHARMACEUTICALS Q1 BASIC EPS USD -0.21
Reuters · 05/13 11:15
MILESTONE PHARMACEUTICALS INC - CASH RESOURCES AS OF MARCH 31, 2024 EXPECTED TO FUND OPERATIONS INTO 2026
Reuters · 05/13 11:15
*Milestone Pharmaceuticals 1Q Loss/Shr 21c >MIST
Dow Jones · 05/13 11:15
*Milestone Pharmaceuticals 1Q Loss $10.4M >MIST
Dow Jones · 05/13 11:15
Press Release: Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update. NDA for etripamil in PSVT resubmitted in 1Q 2024. Cash resources as of March 31, 2024 expected to fund operations into 2026. Dialogue with FDA to finalize Phase 3 protocol for eripamIL in AFib-RVR is progressing. Company on track for potential FDA approval of CARDAMYST nasal spray in the first half of 2025.
Dow Jones · 05/13 11:15
Press Release: Milestone Pharmaceuticals Reports -2-
This press release contains forward-looking statements. Milestone Pharmaceuticals Inc. Faces risks and uncertainties. Actual results may differ from those expressed or implied. Risks include the timing of the launch of etripamil and the potential of the drug to help patients living with heart arrythmias.
Dow Jones · 05/13 11:15
Weekly Report: what happened at MIST last week (0506-0510)?
Weekly Report · 05/13 09:02
Milestone Pharmaceuticals: Q1 Earnings Snapshot
Milestone Pharmaceuticals Inc. Reported a loss of $ million in its first quarter. The Montreal-based company said it had a per-share loss of 21 cents. The results exceeded Wall Street expectations for the quarter. The company reported a profit of $1.2 million in the fourth quarter.
Barchart · 05/13 06:14
Milestone Pharmaceuticals Inc <MIST.OQ> expected to post a loss of 26 cents a share - Earnings Preview
Milestone Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview. The company is expected to show a fall in quarterly revenue when it reports results on May 9. LSEG's mean analyst estimate for the company is for a Loss of 26 cents per share.
Reuters · 05/07 15:12
Weekly Report: what happened at MIST last week (0429-0503)?
Weekly Report · 05/06 09:02
Weekly Report: what happened at MIST last week (0422-0426)?
Weekly Report · 04/29 09:02
More
Webull provides a variety of real-time MIST stock news. You can receive the latest news about Milestone Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About MIST
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.